Search PubMed⌕ Search

Biomedical subjects

O Mayer

Publications and source records attributed to O Mayer.

At least 55 records · Page 3Linked to original sources
PubMed1992

[24-hour effect and tolerance for perindopril (Prestarium) in mild and moderate essential hypertension].

A multicentre investigation of antihypertensive treatment by perindopril was conducted in three centres of Czechoslovakia. The investigation comprised 51 patients with mild to moderate essential hypertension (diastolic pressure 95-115 mmHg) who were taking perindopril for a period of three months, the initial dose being 4 mg (1 tablet per day). If the blood pressure did not drop to normal levels (dBP < 90 mmHg), the dose was increased to 8 mg after 1 month and if after 2 months of treatment the blood pressure did not reach normal levels, a thiazide diuretic was added. The antihypertensive effectiveness was assessed 24 hours after ingestion of the drug. The blood pressure declined significantly already after the first month of monotherapy with perindopril. It declined then significantly up to the end of the 3rd month of treatment. The systolic blood pressure declined by 9.4 mmHg after the first month of monotherapy with perindopril and by 15.9 mmHg after 3 months of treatment. The diastolic blood pressure declined by 8.1 mmHg after one month of monotherapy and by 12.4 mmHg at the end of three-month treatment. The clinical and biological tolerance was excellent and only one patient discontinued treatment for reasons not related to the administered drug. Twenty-four hour monitoring of the blood pressure also proved the favourable effect of perindopril.

Adolescent↗
PubMed1991

Bopindolol: Czechoslovak experience with a new beta blocker in the treatment of hypertension.

Bopindolol is a nonselective beta blocker with mild intrinsic sympathomimetic activity. One of the drug's main benefits is its prolonged effect, lasting for 24 hours, which makes it possible to administer bopindolol in a single daily dose, a fact that may improve patient adherence to therapy. A double-blind study was performed in two centers, comparing bopindolol with metoprolol in 86 hypertensive patients. Baseline diastolic blood pressure (BP) was 100 to 120 mm Hg. The effects of bopindolol or metoprolol on BP and heart rate were similar: return to normal values was achieved in 70% of patients with either drug. A 6-month study at another center found that bopindolol did not affect the levels of total cholesterol, low-density and high-density lipoprotein cholesterol or triglycerides. Another 12-month study documented a decrease in total cholesterol, apolipoprotein (apo) A1 and apo B. The apo A/B ratio rose, thus improving the atherosclerotic index. No deterioration of glucose tolerance or immunoreactive insulin response to glucose was seen after 6 months of bopindolol administration. Bopindolol satisfactorily modifies not only resting but also exercise BP during isometric and isotonic load, thus reducing BP fluctuation during physical activities of the hypertensive patient. The drug exerts no effect on renal and liver function, electrolyte balance and hematologic parameters. Bopindolol is a very useful drug of first choice in mild and moderate hypertension. Bopindolol's main advantages include its prolonged action, good tolerance and a beneficial effect on risk factors of atherosclerosis (lipid and carbohydrate metabolism).

Adolescent↗
PubMed1991

Isradipine in the treatment of hypertension. Some additional effects observed during a one-year study.

After a placebo run-in phase of four weeks' duration, 1.25 mg or 2.5 mg isradipine twice daily orally was administered for one year to 23 patients who had been diagnosed as hypertensive. Good control of blood pressure was recorded in the majority of patients until the third month of treatment. After five months, it was necessary to add a beta-blocker to the treatment regimens of some of the patients in order to maintain the target blood pressure of 140/90 mm Hg. Patients were exercise-tested using bicycle ergometry. After three months, diastolic blood pressure was significantly lower during exercise when comparing the treatment values with those taken at the end of the placebo run-in (baseline values). Values for systolic blood pressure did not differ between treatment and baseline. These results may be explained by the decrease in peripheral vascular resistance produced by isradipine. After one year, the results were modified by the administration of the beta-blocker bopindolol (Sandonorm, Sandoz Pharma Ltd., Basle, Switzerland). Total cholesterol, high-density lipoprotein cholesterol, and apolipoprotein B levels did not change during treatment. Triglycerides were lower after three months, but slightly higher after one year, with an average value lying within the normal range. The influence of isradipine on plasma renin activity (PRA) and aldosterone levels was followed by measuring values at rest and during exercise. It was found that PRA was higher during the first three months, then inversely inhibited to lower levels. Aldosterone levels were also increased after three months, but without a subsequent decrease. The results are compared with those obtained with diltiazem in a similar treatment regimen.

Adult↗
PubMed1991

[Kinetics of metipranolol in patients with chronic kidney failure and during hemodialysis].

The authors investigated the metipranolol plasma concentration in seven patients with renal failure after a single dose of 20 mg of the preparation (2 tablets of Trimepranol) by the oral route during haemodialysis and on days without dialysis, and evaluated also the effect of dialysis on selected pharmacokinetic constants. Although there was a great individual variability of plasma concentrations of metipranolol, these concentrations were at the end of dialysis lower than during the corresponding interval between dialyses. The mean values of the area beneath the concentration curve, the velocity elimination constants, the half-life of elimination and total clearance indicate a certain dialysability of metipranolol. During the practical application of these conclusions it is, however, important to consider the effect on blood pressure and cardiac rhythm resp. by changes of volume and the composition of the extracellular fluid caused by haemodialysis.

Adult↗
PubMed1987

Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension.

The paper offers therapeutic experience with guanfacine (Estulic Sandoz) in large and small doses in patients with hypertension. A daily dose of 3-4 mg of guanfacine led to a decrease in blood pressure in about half of patients with moderate to severe hypertension. However, therapy had to be discontinued in several instances due to frequent occurrence of adverse side effects. The recently recommended smaller doses (2 x 1 mg) of guanfacine indicated primarily in patients with renal dysfunction or diabetes mellitus resulted in an extremely good therapeutic response; the frequency of undesirable effects was about the same as with other antihypertensive therapeutic protocols. The drug seems to offer more benefits in special indications with a concomitant disease rather than as a third drug of a combination used in severe hypertension.

Adult↗